ClinicalTrials.gg
Sign In

DrugBiological

Ifinatamab deruxtecan clinical trials

Also written DS-7300a and MK-2400.

studies test it
14
open now
11
in phase 3
3
first study started
2019

Keep track of what changes. Save the ifinatamab deruxtecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Ifinatamab deruxtecan
9
I-DXd
9
Ifinatamab Deruxtecan (I-DXd)
4

Development codes

DS-7300a
9
MK-2400
8

Studies by the year they started

14 studies that test it; most in 2025 (6)

Studies that test ifinatamab deruxtecan, by start year
YearStudies
20191
20201
20221
20242
20256
20263

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
11
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it.

Small Cell Lung Carcinoma
4
Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Prostatic Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1

Who runs them

Industry 14 · Other 0

Merck Sharp & Dohme LLC (8) · Daiichi Sankyo (5) · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Often tested with

Tested in the same studies.

Atezolizumab (2) · Gocatamig (2) · Raludotatug deruxtecan (2) · Serotonin 5-HT3 Receptor Antagonists (1) · Neurokinin-1 Receptor Antagonists (1)

Studies

Open first, then newest update. How each study uses ifinatamab deruxtecan is read from its arms, and is right about nine times in ten.

Testing it · 14

Given in every arm · 3 — ifinatamab deruxtecan is usual care beside what is tested

Codes

What other systems call ifinatamab deruxtecan · ClinicalTrials.gg INT016190

  • UNII (FDA) C6I0GC0GX5IFINATAMAB DERUXTECANOne source FDA
  • NCI Thesaurus C171577Ifinatamab DeruxtecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.